Biological products; blood specificity designators; technical amendments--FDA. Final rule; technical amendments

The Food and Drug Administration (FDA) is amending the biologics regulations to correct certain omissions from the designators for blood specificities and make other minor, technical amendments. This action is being taken to clarify and improve the accuracy of the regulations.